Theres no accurate Australian data available (the companies who manufacture the drugs dont release their sales figures) but there was an increase in monthly prescriptions in the U.S
GLP-1 might be recommended for anyone who struggles with insulin resistance or prediabetes
NICE guidance (NG28) recommends GLP-1 receptor agonists for adults with type 2 diabetes according to specific criteria, including BMI thresholds and previous therapy response
With semaglutide delivering up to 15% weight loss in clinical trials and tirzepatide reaching 20% or more, alongside significant A1C improvements, it is no surprise patch companies want in
Lowering prices might encourage more people who might benefit from these medications to start using them. Recently, the IIFH brought together leading scientists, industry innovators and health care experts to examine how GLP-1-based therapies are transforming obesity and diabetes care
Medicare Coverage Expansion: The Medicare GLP-1 Bridge (July 2026) and BALANCE Model (January 2027) will bring millions of Medicare beneficiaries into GLP-1 coverage for the first time